DARE News & Events

Dare Bioscience announced receipt of a revised Notice of Award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, a division of the National Institutes of Health, relating to the approximately $2.0 million funding award for DARE-PTB1, Dare's investigational intravaginal ring for the prevention of preterm birth. The notice, issued March 11, 2026, extends the budget and project period for the second tranche of the award, or approximately $1.0 million, through November 30, 2026. The total NIH funding obligated under the program is approximately $2.0 million. DARE-PTB1 is a novel, investigational IVR designed to deliver bio-identical progesterone continuously for up to a 14-day period. It is being developed to reduce the risk of preterm birth in at-risk women, a condition for which there are currently no FDA-approved treatments.

Dare Bioscience announced that the U.S. Food and Drug Administration, FDA, has cleared the Company's Investigational New Drug, IND, application for DARE-HPV, an investigational, proprietary fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert, allowing initiation of a planned Phase 2 clinical study to evaluate DARE-HPV as a potential treatment for persistent high-risk human papillomavirus infection. "FDA clearance to proceed to Phase 2 represents an important regulatory milestone for DARE-HPV and for women who currently have no treatment options for persistent high-risk HPV infection," said Sabrina Johnson, President and CEO of Dare Bioscience. "For decades, women have been told to 'watch and wait' to see if the virus clears on its own. If it does not, the only option has been surgery once precancerous changes appear. DARE-HPV is designed to intervene earlier - targeting the virus itself before progression to cervical disease - aiming to eliminate the frequent "watchful waiting" visits to a health care provider that are costly, burdensome, and contribute to socioeconomic and racial disparities in cervical cancer."

Dare Bioscience announced the availability of telehealth consultations for DARE to PLAY Sildenafil Cream, a proprietary topical arousal cream designed specifically for women to enhance genital blood flow and arousal response. This marks the first time women nationwide can begin the process of obtaining a prescription for a clinically studied, topical sildenafil cream designed specifically for female sexual arousal. "Many women experience sexual health concerns but have not yet connected with a healthcare provider about them," said Sabrina Johnson, President and Chief Executive Officer of Dare Bioscience. "Telehealth access through the DARE Health Hub provides a convenient opportunity to connect with knowledgeable healthcare providers without an in-person visit or needing to schedule an appointment. We are pleased that women can now take proactive steps to access DARE to PLAY in all 50 continental states in the U.S.. We believe DARE to PLAY(TM) represents a long overdue correction, giving women an option to reconnect with their own bodies, their pleasure, and their confidence, using science that finally recognizes their needs."

Dare Bioscience announced that providers in select states can now begin prescribing DARE to PLAY Sildenafil Cream, a proprietary topical arousal cream designed specifically for women to enhance genital blood flow and arousal response. "When Viagra was approved in 1998, it revolutionized sexual medicine for men. But for women, comparable progress on enhancing the natural arousal sensations has stalled for nearly three decades," said Sabrina Martucci Johnson, President and CEO of Dare Bioscience. "We believe DARE to PLAY represents a long overdue correction, giving women an option to reconnect with their own bodies, their pleasure, and their confidence, using science that finally recognizes their needs."